- In November 2024, Shuttle Pharma has expanded its Phase II trial of ropidoxuridine for glioblastoma patients, with the first cohort dosed at cancer centers across the US. The treatment, which combines with radiation therapy, is being tested for its potential in combating glioblastoma. This expansion will enhance the company's position in the glioblastoma treatment market, demonstrating its commitment to advancing innovative cancer therapies
- In July 2024, aTyr Pharma, Inc. has signed a research agreement with Stanford Medicine, with Dr. Michael Lim, Chair of Neurosurgery, serving as the principal investigator. Dr. Lim’s research will focus on the mechanisms of immunosuppression in glioblastoma multiforme (GBM). This collaboration will enhance aTyr Pharma's expertise and research capabilities, advancing its efforts to develop novel immunotherapies for GBM
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment Type (Chemotherapy, Radiation Therapy, Surgical Treatment, Immunotherapy, Targeted Therapy, and Stem Cell Therapy), Drug Type (Chemotherapeutic Agents, Targeted Therapies, Immunotherapies, and Others), Clinical Stage (Early Stage GBM and Late Stage GBM), Patient Type (Adult Patients and Pediatric Patients), End User (Hospitals, Specialized Cancer Clinics, and Ambulatory Surgery Centers) – Industry Trends and Forecast to 2032
.
The Global Glioblastoma Multiforme Treatment Market size was valued at USD 3.09 USD Billion in 2024.
The Global Glioblastoma Multiforme Treatment Market is projected to grow at a CAGR of 8.9% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
